Theravance Biopharma Inc (NASDAQ:TBPH) — Market Cap & Net Worth
Market Cap & Net Worth: Theravance Biopharma Inc (TBPH)
Theravance Biopharma Inc (NASDAQ:TBPH) has a market capitalization of $854.78 Million ($854.78 Million) as of June 17, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #9779 globally and #2623 in its home market, demonstrating a 2.46% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Theravance Biopharma Inc's stock price $16.69 by its total outstanding shares 51492924 (51.49 Million). Review Theravance Biopharma Inc debt and liabilities to assess the company's total debt and financial obligations.
Theravance Biopharma Inc Market Cap History: 2015 to 2026
Theravance Biopharma Inc's market capitalization history from 2015 to 2026. Data shows growth from $843.97 Million to $859.42 Million (1.72% CAGR).
Index Memberships
Theravance Biopharma Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.43 Trillion | 0.04% | #267 of 976 |
|
NASDAQ Composite
IXIC
|
$41.27 Trillion | 0.00% | #1006 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.70 Trillion | 0.05% | #153 of 263 |
Weight: Theravance Biopharma Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Theravance Biopharma Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Theravance Biopharma Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
8.97x
Theravance Biopharma Inc's market cap is 8.97 times its annual revenue
Latest Price to Earnings (P/E) Ratio
9.10x
Theravance Biopharma Inc's market cap is 9.10 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $1.64 Billion | $48.65 Million | -$190.67 Million | 33.74x | N/A |
| 2017 | $1.44 Billion | $15.39 Million | -$285.40 Million | 93.34x | N/A |
| 2018 | $1.32 Billion | $60.37 Million | -$215.52 Million | 21.83x | N/A |
| 2019 | $1.33 Billion | $73.41 Million | -$236.46 Million | 18.16x | N/A |
| 2020 | $915.03 Million | $71.86 Million | -$278.02 Million | 12.73x | N/A |
| 2021 | $569.00 Million | $55.31 Million | -$199.43 Million | 10.29x | N/A |
| 2022 | $577.75 Million | $51.35 Million | $872.13 Million | 11.25x | 0.66x |
| 2023 | $578.78 Million | $57.42 Million | -$55.19 Million | 10.08x | N/A |
| 2024 | $484.55 Million | $64.38 Million | -$56.42 Million | 7.53x | N/A |
| 2025 | $963.43 Million | $107.46 Million | $105.89 Million | 8.97x | 9.10x |
Competitor Companies of TBPH by Market Capitalization
Companies near Theravance Biopharma Inc in the global market cap rankings as of June 17, 2026.
Key companies related to Theravance Biopharma Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #442 globally with a market cap of $63.33 Billion USD.
- UCB SA (BR:UCB): Ranked #550 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #574 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $453.17 |
| #442 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $63.33 Billion | $614.73 |
| #550 | UCB SA | BR:UCB | $49.68 Billion | €250.00 |
| #574 | Argen-X | BR:ARGX | $47.14 Billion | €755.80 |
Theravance Biopharma Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Theravance Biopharma Inc's market cap moved from $843.97 Million to $ 859.42 Million, with a yearly change of 1.72%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $859.42 Million | -10.80% |
| 2025 | $963.43 Million | +98.83% |
| 2024 | $484.55 Million | -16.28% |
| 2023 | $578.78 Million | +0.18% |
| 2022 | $577.75 Million | +1.54% |
| 2021 | $569.00 Million | -37.82% |
| 2020 | $915.03 Million | -31.36% |
| 2019 | $1.33 Billion | +1.17% |
| 2018 | $1.32 Billion | -8.25% |
| 2017 | $1.44 Billion | -12.52% |
| 2016 | $1.64 Billion | +94.51% |
| 2015 | $843.97 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 17th, 2026 the market cap of Theravance Biopharma Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $854.78 Million USD |
| MoneyControl | $854.78 Million USD |
| MarketWatch | $854.78 Million USD |
| marketcap.company | $854.78 Million USD |
| Reuters | $854.78 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Theravance Biopharma Inc
Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, an once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD); and Ampreloxetine an investigational, once-daily norepinephrine reuptake inhibitor, Which is in Phase 3 clinical trials for symptomatic n… Read more